Pramipexole use and the risk of pneumonia

BMC Neurology

Table 4 Adjusted rate ratios of pneumonia associated with current use of pramipexole relative to non-current use, stratified by history of pneumonia prior to cohort entry and use of anti- parkinsonian medication prior to the 180-day period before the index date

	Cases	Controls	Adjusted*		P-value for interaction
	Cases	Controls	Rate ratio	95% CI	P-value for interaction
Number of subjects	1835	16088
History of pneumonia	4/127	23/564	0.66	0.22 – 2.00	0.81
No history of pneumonia	55/1708	711/15524	0.75	0.56 – 1.01
Levodopa use	36/1524	461/13128	0.71	0.49 – 1.01	0.43
No levodopa use	23/311	273/2960	0.90	0.55 – 1.45
Any dopamine agonist use	46/437	602/3993	0.67	0.48 – 0.95	0.44
No dopamine agonist use	13/1398	132/12095	0.89	0.47 – 1.66
Ergot-derived dopamine agonist use	14/258	148/2082	0.69	0.38 – 1.24	0.80
No ergot-derived dopamine agonist use	45/1577	586/14006	0.75	0.54 – 1.04

* Adjusted for current use of other dopamine agonists, other anti-parkinsonian drugs and selected.
factors from Table 1, namely age, duration of APK use, obesity, smoking, alcohol, cerebrovascular, ischemic heart disease, hypertension, heart failure, diabetes, edema, COPD, asthma, prior pneumonia, lung cancer, other cancer, depression, anemia, renal failure, vaccination (influenza and pneumonia), PPIs, NSAIDs, oral corticosteroids, other respiratory medications, antibiotics, antipsychotics and antidepressants.
‡ Current use refers to a prescription ending after or within 30 days prior to the index date.
‡ Previous timing of covariate refers to the period prior to 180 days before the index date.

ISSN: 1471-2377